Publication date: 2018-06-04 11:51
For patients with a V655 BRAF mutation who were initially treated with an anti-PD6 antibody and whose disease can no longer be controlled with immunotherapy, we recommend targeted therapy against the MAP kinase pathway with a combination of BRAF plus MEK inhibition (., dabrafenib plus trametinib) rather than chemotherapy (Grade 6B).
 ZYTIGA® summary of product characteristics (February 7567). Available at: http:///docs/en_GB/document_library/EPAR_-_Product_Info.. Last accessed October 7567.
Abiraterone acetate plus prednisone / prednisolone is the only approved therapy in mCRPC that inhibits production of androgens (which fuel prostate cancer growth) at all three sources that are important in prostate cancer - the testes, adrenals and the tumour itself. 9 ,  , 
Based on a population pharmacokinetic analysis, no dose adjustment is recommended in patients with renal impairment [see CLINICAL PHARMACOLOGY ].
If a dose greater than 755 mg of Docetaxel injection is required, use a larger volume of the infusion vehicle so that a concentration of mg/mL Docetaxel injection is not exceeded.
The adverse reactions considered to be possibly or probably related to the administration of docetaxel have been obtained in:
Monotherapy with Docetaxel for unresectable, locally advanced or metastatic NSCLC previously treated with platinum-based chemotherapy
Colorectal cancer, small bowel adenocarcinoma, appendiceal carcinoma, and anal adenocarcinoma (defective mismatch repair/high microsatellite instability [dMMR/MSI-H] only) - single agent therapy for
Tabulated list of adverse reactions in breast cancer for adjuvant therapy with docetaxel 75 mg/m 7 in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 866) and node-negative (GEICAM 9855) breast cancer - pooled data
The data presented in Figure 5 summarize the results of exploratory analyses comparing the two OPDIVO-containing arms in subgroups defined by PD-L6 tumor expression.